Twenty-four-hour diurnal curve comparison of commercially available latanoprost 0.005% versus the @entity6839 and XXXX fixed combination.

@entity1 @entity1538 @entity101 @entity15438 @entity6839 @entity565 @entity2790
PURPOSE: To evaluate the efficacy and safety of commercially available latanoprost 0.005% given every evening versus @entity6839 0.5% and @entity15438 2% fixed combination (TDFC) given twice daily to white Greeks with primary @entity1538 and ocular @entity101 @entity1 . DESIGN: A single-masked, two-center, crossover comparison with two 6-week treatment periods occurring after at least a 3-week medicine-free period. Diurnal curve intraocular pressures were taken at 2:00 AM, 6:00 AM, 10:00 AM, 2:00 PM, 6:00 PM, and 10:00 PM. @entity1 : Thirty-four subjects with primary @entity1538 or @entity2790 were enrolled. INTERVENTIONS: Latanoprost 0.005% given every evening and TDFC twice daily. MAIN OUTCOME MEASURES: The primary efficacy variable was diurnal intraocular pressure. RESULTS: Thirty-three @entity1 completed the study. On the last day of treatment, the mean diurnal intraocular pressure for latanoprost was 15.9 +/- 2.3 mmHg and for TDFC was 15.3 +/- 2.0 mmHg (P = 0.05). Individual time points for intraocular pressure were not statistically different between groups except at the 10:00 PM time point, when the mean for TDFC was 14.6 +/- 2.7 mmHg and for latanoprost was 16.6 +/- 3.1 mmHg (P < 0.006). Eighteen @entity1 overall preferred latanoprost versus 2 @entity1 for the fixed combination, generally because of the greater convenience of once daily dosing. Adverse events were not significantly different between groups except that a bitter taste was found more frequently with TDFC (n = 9) than with latanoprost (n = 0; P = 0.009). Despite screening to exclude intolerance to beta-blockers, a single @entity1 had to discontinue the TDFC because of new-onset @entity565 . CONCLUSIONS: This study indicates that the 24-hour diurnal intraocular pressure is lowered more, by a small but statistically significant amount, with TDFC compared with latanoprost in primary @entity1538 and ocular @entity101 @entity1 .
